X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (20) 20
humans (16) 16
animals (14) 14
mice (13) 13
female (12) 12
oncology (12) 12
pharmacology & pharmacy (9) 9
cancer (8) 8
colorectal cancer (7) 7
mice, nude (7) 7
pharmacology (7) 7
xenograft model antitumor assays (7) 7
breast-cancer (6) 6
cell line, tumor (6) 6
article (5) 5
cell proliferation - drug effects (5) 5
drug dosages (5) 5
expression (5) 5
cell lung-cancer (4) 4
colon-cancer (4) 4
colorectal neoplasms - drug therapy (4) 4
mice, inbred balb c (4) 4
pharmacokinetics (4) 4
phase-i (4) 4
xenografts (4) 4
adult (3) 3
advanced solid tumors (3) 3
animal models (3) 3
antitumor-activity (3) 3
apoptosis (3) 3
cell lines (3) 3
cells (3) 3
chemotherapy (3) 3
dose-response relationship, drug (3) 3
growth (3) 3
kinases (3) 3
male (3) 3
models (3) 3
mutation (3) 3
original research (3) 3
research article (3) 3
signal transduction - drug effects (3) 3
studies (3) 3
therapy (3) 3
tissue distribution (3) 3
tumors (3) 3
1-phosphatidylinositol 3-kinase (2) 2
abridged index medicus (2) 2
adenocarcinoma (2) 2
akt protein (2) 2
analysis (2) 2
antineoplastic agents - pharmacokinetics (2) 2
antineoplastic combined chemotherapy protocols - pharmacology (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
apoptosis - drug effects (2) 2
biology (2) 2
biotechnology (2) 2
body-mass index (2) 2
camptothecin - analogs & derivatives (2) 2
camptothecin - pharmacology (2) 2
cancer treatment (2) 2
cell cycle (2) 2
chemistry, medicinal (2) 2
clinical trials (2) 2
colorectal carcinoma (2) 2
colorectal neoplasms - metabolism (2) 2
digestive system diseases (2) 2
dna-damage-response (2) 2
docetaxel (2) 2
dosing (2) 2
drug design (2) 2
drug development (2) 2
drug synergism (2) 2
endocrinology & metabolism (2) 2
endothelial growth-factor (2) 2
experimental design (2) 2
follicle stimulating hormone - blood (2) 2
growth-factor receptor (2) 2
health aspects (2) 2
immunology (2) 2
in-vitro (2) 2
inhibitor (2) 2
intrinsic resistance (2) 2
irinotecan (2) 2
k-ras protein (2) 2
luteinizing hormone - blood (2) 2
magnetic resonance imaging - methods (2) 2
medicine (2) 2
metabolism (2) 2
models, biological (2) 2
multidisciplinary sciences (2) 2
nanoparticles (2) 2
neoplasm transplantation (2) 2
neoplasms - drug therapy (2) 2
neoplasms - metabolism (2) 2
neoplasms - pathology (2) 2
obesity - blood (2) 2
oncology agents (2) 2
p53 (2) 2
pf-3758309 (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 11/2014, Volume 9, Issue 11, pp. e113037 - e113037
Background: The activation of the MAPK and PI3K/AKT/mTOR pathways is implicated in the majority of cancers. Activating mutations in both of these pathways has... 
BREAST-CANCER | CARCINOMA-CELLS | COLON-CANCER | SIGNALING PATHWAY | MULTIDISCIPLINARY SCIENCES | ORAL MEK INHIBITOR | SMALL-CELL LUNG | TUBEROUS SCLEROSIS | ANTITUMOR-ACTIVITY | PHASE-I | PREVIOUSLY TREATED PATIENTS | Diphenylamine - pharmacology | TOR Serine-Threonine Kinases - metabolism | Humans | Immunoblotting | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | TOR Serine-Threonine Kinases - antagonists & inhibitors | Diphenylamine - analogs & derivatives | Colorectal Neoplasms - drug therapy | Female | Benzamides - pharmacology | Colorectal Neoplasms - metabolism | Antineoplastic Combined Chemotherapy Protocols | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Signal Transduction - drug effects | Mice, Nude | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Mitogen-Activated Protein Kinases - metabolism | Models | Health aspects | Analysis | Colorectal cancer | TOR protein | Cell culture | Biotechnology | Downstream effects | Colorectal carcinoma | Clinical trials | Oncology | AKT protein | Kinases | K-Ras protein | Cell growth | Pathways | Xenografts | Drug dosages | Pharmaceutical sciences | Extracellular signal-regulated kinase | MAP kinase | Pharmacology | Tumor cell lines | Patients | 1-Phosphatidylinositol 3-kinase | Medicine | Inhibitors | Cell lines | Certificates of need | Mutation | Cancer | Apoptosis | Tumors | Index Medicus
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2013, Volume 8, Issue 3, pp. e58089 - e58089
Purpose: The PI3K/AKT/mTOR pathway is frequently dysregulated in cancers and inhibition of mTOR has demonstrated the ability to modulate pro-survival pathways.... 
RAD001 EVEROLIMUS | MAMMALIAN TARGET | COLON-CANCER | ADVANCED SOLID TUMORS | PHARMACOKINETICS | MULTIDISCIPLINARY SCIENCES | TYROSINE KINASE INHIBITOR | PIK3CA MUTATION | RAT-BRAIN | MTOR INHIBITORS | PHASE-I | Neoplasm Transplantation | ras Proteins - genetics | Colonic Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) | Colonic Neoplasms - drug therapy | Humans | ras Proteins - metabolism | Transplantation, Heterologous | Phosphatidylinositol 3-Kinases - metabolism | Colonic Neoplasms - metabolism | Female | Everolimus | Immunosuppressive Agents - pharmacology | Proto-Oncogene Proteins B-raf - metabolism | Camptothecin - analogs & derivatives | Proto-Oncogene Proteins - metabolism | Antineoplastic Agents, Phytogenic - agonists | Sirolimus - analogs & derivatives | Proto-Oncogene Proteins - genetics | Immunosuppressive Agents - agonists | Sirolimus - pharmacology | Metabolome - genetics | Sirolimus - agonists | Drug Synergism | Phosphatidylinositol 3-Kinases - genetics | Xenograft Model Antitumor Assays | Animals | Class I Phosphatidylinositol 3-Kinases | Metabolome - drug effects | Mice, Nude | Proto-Oncogene Proteins B-raf - genetics | Camptothecin - agonists | Colonic Neoplasms - pathology | Cell Line, Tumor | Mice | Mutation | Antineoplastic Agents, Phytogenic - pharmacology | Camptothecin - pharmacology | Prevention | Angiogenesis inhibitors | Colorectal cancer | Cancer | TOR protein | Biotechnology | Metabolomics | Animal models | Nuclear magnetic resonance--NMR | Colorectal carcinoma | Cytotoxicity | Lipids | AKT protein | Oncology | Metastasis | Kinases | Cancer therapies | K-Ras protein | Anticancer properties | Signal transduction | Xenografts | Bioindicators | Inhibition | Growth factors | Drug dosages | Quantitative analysis | Dosing | Pharmacology | Metabolism | 1-Phosphatidylinositol 3-kinase | Studies | Irinotecan | Chemotherapy | Experimental design | Medical prognosis | Cell lines | Glycolysis | Biomarkers | Antitumor activity | Anesthesiology | Combinatorial analysis | Tumors | Index Medicus | Nuclear magnetic resonance | NMR
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 01/2008, Volume 97, Issue 1, pp. 237 - 250
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2007, Volume 13, Issue 9, pp. 2768 - 2776
Purpose: Docetaxel (Taxotere), an important chemotherapeutic agent with shown activity in a broad range of cancers, is being investigated for use in... 
PBPK | pharmacokinetic | docetaxel | mice | interspecies scaling | CELL LUNG-CANCER | IN-VITRO | ONCOLOGY | TISSUE DISTRIBUTION | TAXOL | METASTATIC BREAST-CANCER | HUMANS | TAXOTERE | TUBULIN | BINDING | PACLITAXEL | Tissue Distribution | Animals | Models, Biological | Humans | Antineoplastic Agents - pharmacokinetics | Mice | Mice, Inbred BALB C | Taxoids - pharmacokinetics | Index Medicus
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 07/2010, Volume 334, Issue 1, pp. 310 - 317
Journal Article
Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 31, pp. 50290 - 50301
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2016, Volume 34, Issue 2, pp. 176 - 183
Background Vandetanib is a multitargeted tyrosine kinase inhibitor that affects vascular endothelial growth factor receptor (VEGF), epidermal growth factor... 
RET | Vandetanib | Phase I | Medicine & Public Health | EGF | Pancreatic cancer | VEGF | Oncology | Pharmacology/Toxicology | Cholangiocarcinoma | PLUS GEMCITABINE | 1ST-LINE TREATMENT | ADENOCARCINOMA | ZD6474 | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | PHARMACOLOGY & PHARMACY | INHIBITOR | EXPRESSION | RECEPTOR TYROSINE KINASE | III TRIAL | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Deoxycytidine - pharmacology | Male | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Piperidines - pharmacology | Adult | Deoxycytidine - adverse effects | Female | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Pancreatic Neoplasms - pathology | Capecitabine - pharmacology | Treatment Outcome | Capecitabine - therapeutic use | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Quinazolines - adverse effects | Aged | Neoplasm Staging | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Cohort Studies | Complications and side effects | Care and treatment | Usage | Clinical trials | Research | Drug therapy, Combination | Health aspects | Studies | Inhibitor drugs | Kinases | Vascular endothelial growth factor | Index Medicus | pancreatic cancer | vandetanib | cholangiocarcinoma
Journal Article
Frontiers in Pharmacology, ISSN 1663-9812, 2015, Volume 6, Issue MAY, pp. 120 - 120
Aurora A kinase and MEK inhibitors induce different, and potentially complementary, effects on the cell cycle of malignant cells, suggesting a rational basis... 
Human tumor xenografts | KRAS mutation | MEK | Aurora A kinase | Alisertib | PIK3CA | Colorectal cancer | Trametinib | colorectal cancer | ADVANCED SOLID TUMORS | ALISERTIB MLN8237 | PHOSPHORYLATION | human tumor xenografts | P53 | trametinib | CETUXIMAB | MELANOMA | THERAPY | alisertib | RAS MUTATIONS | SELUMETINIB | PHARMACOLOGY & PHARMACY | PHASE-I
Journal Article